Additionally, we have studied data on the sensitivity of AML, CML and NB cells to several FGFR-family (AZD4547, FGFR_3831, and PD173074), NTRK-family (AZD1332 and GW441756) and KIT inhibitors (imatinib, sunitinib, and sorafenib) available at CancerRxGene [45] and revealed that average geometric mean of KIT inhibitors was lower than for FGFR and NTRK targeting drugs (Figure S4a). This evidence concerns the gene KIT and acute myeloid leukemia.